Drug Profile
Research programme: retinol-binding protein 4 antagonists - iCura Vision
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Columbia University; iCura Vision; National Institutes of Health (USA)
- Class Small molecules
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (PO)
- 28 Jan 2015 Preclinical trials in Age-related macular degeneration in USA (PO)